Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
Thuy Trang Nguyen,
Qui Thanh Hoai Ta,
Thi Kim Oanh Nguyen,
Thi Thuy Dung Nguyen,
Van Giau Vo
Affiliations
Thuy Trang Nguyen
Faculty of Pharmacy, Ho Chi Minh City University of Technology (HUTECH), Ho Chi Minh City 700000, Vietnam
Qui Thanh Hoai Ta
Institute of Research and Development, Duy Tan University, Danang 550000, Vietnam
Thi Kim Oanh Nguyen
Faculty of Food Science and Technology, Ho Chi Minh City University of Food Industry, Ho Chi Minh City 700000, Vietnam
Thi Thuy Dung Nguyen
Faculty of Environmental and Food Engineering, Nguyen Tat Thanh University, Ho Chi Minh City 70000, Vietnam
Van Giau Vo
Department of Industrial and Environmental Engineering, Graduate School of Environment, Gachon University, 1342 Sungnam-daero, Sujung-gu, Seongnam-si, Gyeonggi-do 461-701, Korea
Alzheimer’s disease (AD) is a complex neurodegenerative disease that requires extremely specific biomarkers for its diagnosis. For current diagnostics capable of identifying AD, the development and validation of early stage biomarkers is a top research priority. Body-fluid biomarkers might closely reflect synaptic dysfunction in the brain and, thereby, could contribute to improving diagnostic accuracy and monitoring disease progression, and serve as markers for assessing the response to disease-modifying therapies at early onset. Here, we highlight current advances in the research on the capabilities of body-fluid biomarkers and their role in AD pathology. Then, we describe and discuss current applications of the potential biomarkers in clinical diagnostics in AD.
